pvp.trade spent $8.68 million in commissions to buy HYPE, with current unrealized profits exceeding $15 million
BlockBeats reported on May 28 that, according to on-chain analyst Yu Jin's monitoring, the Hyperliquid TG trading bot and copy trading platform pvp.trade has accumulated approximately $8.68 million in income through trading fee commissions, making it one of the leading Builders in the Hyperliquid ecosystem.
After Hyperliquid issued its token, pvp.trade has continued to use its commission income to purchase HYPE. So far, it has used $8.68 million to acquire 421,000 HYPE tokens at an average cost of only $20.6. As HYPE has increased in price, the value of its holdings has now risen to around $24.34 million.
However, pvp.trade has redeemed 400,000 HYPE from staking yesterday, worth approximately $22.8 million, and it is not yet clear whether it plans to take profits at the current high.
The Builder Fees mechanism of Hyperliquid allocates a portion of the trading fees to products built by Builders when users trade using these products.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Janus Henderson Macro Head Says Market Is Near Its Top but Cannot Say When
A $5.7 billion patent verdict has been issued, Burford Capital (BUR.US) may receive $1.4 billion, and its share price soared by more than 12%.
Burford Capital Ltd. surged more than 12% on Monday, marking its largest intraday increase since the end of March, after a federal jury delivered a verdict in a patent case involving Apple.
Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request
A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.
After years of waiting and another delay, Tesla (TSLA.US) postpones the Roadster debut to October 15 as severe weather forces the event to stop.
Tesla has rescheduled the unveiling event for its next-generation Roadster, originally planned for this week, to October 15.
Crypto prices
More
